Biolase, Inc. BIOLQ
0.00
0.00
NaN
as of 23 Sep
- Market cap
- $2.3M
- P/E
- 0.0×
Follow BIOLQ
Growth Flags
show if company had growth for consecutive years
| Sep '24 | Jun '24 | Mar '24 | Dec '23 | Older periods | |
|---|---|---|---|---|---|
P/E ratio |
0.00 | 0.00 | 0.00 | 0.00 |
+8 more quarters Free account |
P/S ratio |
0.05 | 0.08 | 0.07 | 0.03 | |
P/FCF ratio |
0.00 | 0.00 | 0.00 | 0.00 | |
P/Operating CF |
(0.56) | (5.00) | (0.57) | (0.62) | |
P/B ratio |
0.00 | 0.00 | 0.00 | 0.00 | |
Price to Tangible BV |
0.00 | 0.00 | 0.00 | 0.00 | |
EV/Sales |
0.33 | 0.26 | 0.23 | 0.18 | |
EV/EBITDA |
0.00 | 0.00 | 0.00 | 0.00 | |
EV/Operating CF |
(1.14) | (1.02) | (0.77) | (0.63) | |
EV/FCF |
(1.16) | (1.03) | (0.75) | (0.58) | |
Quick Ratio |
0.23 | 0.32 | 0.56 | 0.61 | |
Current Ratio |
0.63 | 0.71 | 1.17 | 1.26 | |
Net Debt/EBITDA |
188.03 | (3.32) | (2.04) | (1.74) | |
Debt/Assets |
58.89% | 43.81% | 40.77% | 40.02% | |
Debt/Equity |
(3.29) | (6.31) | 52.07 | 7.18 | |
Asset Turnover |
1.40 | 1.31 | 1.28 | 1.34 | |
Operating CF/Net income |
3.13 | 0.26 | 0.92 | 0.10 | |
Capex/Depreciation |
0.04 | 0.08 | 0.25 | 0.00 | |
Interest Coverage |
0.00 | 0.00 | 0.00 | 0.00 | |
Research and Development Expense of Revenue |
8.45% | 9.27% | 12.66% | 12.24% | |
Selling, General and Administrative Expense of Revenue |
38.34% | 58.49% | 64.94% | 51.51% | |
Intangible Assets out of Total Assets |
0.11 | 0.10 | 0.09 | 0.08 | |
Share Based Compensation of Revenue |
0.47% | (0.40%) | 9.31% | 1.35% | |
Graham Net Nets |
(5.03) | (2.91) | (2.68) | (5.89) | |
Graham Number |
2.70 | 4.21 | 6.04 | 11.90 | |
Earnings Yield |
(3,200.00%) | (5,536.36%) | (7,863.16%) | (2,961.82%) | |
Free Cash Flow Yield |
(520.19%) | (312.31%) | (434.10%) | (1,082.66%) | |
Revenue per Share |
0.30 | 0.35 | 0.57 | 10.56 | |
Operating CF per Share |
(0.12) | (0.02) | (0.33) | (1.79) | |
Capex per Share |
0.00 | 0.00 | 0.01 | 0.00 | |
Free Cash Flow per Share |
(0.12) | (0.02) | (0.32) | (1.79) | |
Cash per Share |
0.10 | 0.16 | 0.36 | 5.14 | |
Shareholders Equity per Share |
(0.14) | (0.06) | 0.02 | 1.53 | |
Interest Debt per Share |
0.00 | 0.00 | 0.00 | 0.00 | |
Book value per Share |
(0.14) | (0.06) | 0.02 | 1.53 | |
Free Cash Flow |
(4.44) | (0.67) | (5.74) | (2.29) | |
Working Capital |
(11.43) | (9.08) | 3.58 | 5.20 | |
Capital Expenditures |
0.03 | 0.06 | 0.20 | 0.00 | |
Net Current Asset Value |
(12.69) | (10.67) | (9.08) | (8.28) | |
EV/EBIT |
0.00 | 0.00 | 0.00 | 0.00 | |
Capex to Sales |
0.00 | (0.01) | (0.02) | 0.00 | |
Net Profit Margin |
(13.16%) | (24.21%) | (64.01%) | (165.40%) | |
Price to Operating Income |
0.00 | 0.00 | 0.00 | 0.00 | |
| Other line items | |||||
Average Receivables |
3.96 | 5.28 | 5.42 | 5.66 | |
Average Payables |
5.09 | 5.90 | 6.23 | 5.93 | |
Average Inventory |
11.85 | 12.12 | 14.52 | 13.66 | |
Average Assets |
32.99 | 35.14 | 38.15 | 36.64 | |
Average Common Equity |
(2.45) | 1.15 | 3.11 | 2.32 |
Columns are period end dates